Chapter PDF
Keywords
- European Union
- Purine Nucleoside Phosphorylase
- Antibacterial Resistance
- Antibiotic Policy
- European Medicine Evaluation Agency
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Appelbaum, P. C., 2003, Bacterial resistance concerns. ASM News, 69(4), 161.
Austin, D. J., Kristinsson, K. G., and Anderson, R. M., 1999, The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proc. Natl. Acad. Sci. USA, 96, 1152–1156.
Ball, P., Baquero, F., Cars, O., File, T., Garau, J., Klugman, K. et al., 2002, Antibiotic therapy of community respiratory tract infections: Strategies for optimal outcomes and minimized resistance emergence. J. Antimicrob. Chemother., 49, 31–40.
Bax, R., Bywater, R., Cornaglia, G., Goossens, H., Hunter, P., Isham, V et al., 2001, Surveillance of antimicrobial resistance—what, how and whither? Clin. Microbiol. Infect., 7, 316–325.
Bax, R., Gabbay, F., Phillips, I., and the Witley Park Study Group, 1999, Antibiotic clinical trials—the Witley Park Symposium. Clin. Microbiol. Infect., 5, 774–788.
Carbon, C., Cars, O., and Christiansen, K., 2002, Moving from recommendation to implementation and audit: Part 1. Current recommendations and programs: a critical commentary. Clin. Microbiol. Infect., 8(Suppl. 2), 92–106.
Chahwakilian, P., 2000, Politiques d’antibiothérapie a l’échelon national dans divers pays. Rev. Pneumol. Clin., 1S, 9–12.
Christiansen, K., Carbon, C., and Cars, O., 2002, Moving from recommendation to implementation and audit: Part 2. Review of interventions and audit. Clin. Microbiol. Infect., 8(Suppl. 2), 107–128.
Davey, P., Nathwani, D., and Rubinstein, E., 2003, Antibiotic policies. In R. Finch, D. Greenwood, S. Norrby, and R. Whitley (eds.), Antibiotic and Chemotherapy. Churchill Livingstone, London.
Diekema, D. I. and Jones, R. N., 2000, Oxazolidinones: A review. Drugs, 59, 7–16.
Felmingham, D., Feldman, C., Hryniewicz, W., Klugman, K., Kohno, S., Low, D. E. et al., 2002, Surveillance of resistance in bacteria causing community-acquired respiratory tract infections. Clin. Microbiol. Infect., 8(Suppl. 2), 12–42.
Finch, R. G. and Low, D. E., 2002, A critical assessment of published guidelines and other decision-support systems for the antibiotic treatment of community-acquired respiratory tract infections. Clin. Microbiol. Infect., 8(Suppl. 2), 69–91.
Garrod, L. P., O’Grady, F., and Lambert, H. P., 1981, The evolution of anti-microbic drugs. In L. P. Garrod, H. P. Lambert, and F. O’Grady (eds.), Antibiotic and Chemotherapy. Churchill Livingstone, London.
Gould, I. M., 1999, A review of the role of antibiotic policies in the control of antibiotic resistance. J. Antimicrob. Chemother., 43, 459–465.
Gould, I. M., 2001a, Introduction. Clin. Microbiol. Infect., 7(Suppl. 6), 1.
Gould, I. M., 2001b, Minimum antibiotic stewardship measures. Clin. Microbiol. Infect., 7(Suppl. 6), 22–26.
Hunter, P. A. and Reeves, D. S., 2002, The current status of surveillance of resistance to antimicrobial agents: Report on a meeting. J. Antimicrob. Chemother., 49, 17–23.
ICAAC, 2002, Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. September 27–30, 2002, American Society for Microbiology, San Diego, CA.
ICAAC, 2003, Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. September 14–17, 2003, American Society for Microbiology, Chicago, IL.
IDSA, 2003, The future of antimicrobial drug availability: An impending crisis. March 12.
Kaitin, K. I. and DiMasi, J. A., 2000, Measuring the pace of new drug development in the user fee era. Drug Inf. J., 34, 673–680.
Koonin, E. V, 2000, How many genes can make a cell: the minimal-gene-set concept. Annu. Rev. Genomics Hum. Genet., 1, 99–116.
Lewis, D., 2002, Antimicrobial resistance surveillance: Methods will depend on objectives. J. Antimicrob. Chemother., 49, 3–5.
Mills, S. D., 2003, The role of genomics in antimicrobial discovery. J. Antimicrob. Chemother., 51, 749–752.
Monnet, D. L. and Sorensen, T. L., 2001, The patient, the doctor, the regulator and the profit maker: Conflicts and possible solutions. Clin. Microbiol. Infect., 7(Suppl. 6), 27–30.
Nathwani, D., Rubinstein, E., Barlow, G., and Davey, P., 2001, Do guidelines for community-acquired pneumonia improve the cost-effectiveness of hospital care? Clin. Infect. Dis., 32, 728–741.
Rasmussen, B. A. and Projan, S. J., 2003, Antibacterial drug discovery: What’s in the pipeline? In R. Finch, D. Greenwood, S. Norrby, and R. Whitley (eds.), Antibiotic and Chemotherapy. Churchill Livingstone, London.
Reynolds, R., and BSAC Extended Working Party on Respiratory Resistance Surveillance, 2001, BSAC Respiratory Resistance Surveillance Programme: First results of the winter 1999–2000 collection. Int. J. Antimicrob. Agents, 17(Suppl. 1), S143. Abstract P127.088.
Schlemmer, B., 2001, Impact of registration procedures on antibiotic policies. Clin. Microbiol. Infect., 7(Suppl. 6), 5–8.
Shlaes, D. M. and Ryan, J. L., 2003, Strategic and regulatory considerations in the clinical development of anti-infectives. In R. Finch, D. Greenwood, S. Norrby, and R. Whitley (eds.), Antibiotic and Chemotherapy. Churchill Livingstone, London.
Watson, J. D. and Crick, F. H., 1953, Molecular structure of nucleic acids: A structure for deoxyribose nucleic acid. Nature, 171, 737–738.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer Science + Business Media, Inc.
About this chapter
Cite this chapter
White, A.R. (2005). The Pharmaceutical Company Approach to Antibiotic Policies. In: Gould, I.M., van der Meer, J.W.M. (eds) Antibiotic Policies. Springer, Boston, MA. https://doi.org/10.1007/0-387-22852-7_34
Download citation
DOI: https://doi.org/10.1007/0-387-22852-7_34
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-306-48500-8
Online ISBN: 978-0-387-22852-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)